1. Home
  2. DFH vs SLBT Comparison

DFH vs SLBT Comparison

Compare DFH & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

N/A

Current Price

$13.80

Market Cap

1.4B

ML Signal

N/A

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

N/A

Current Price

$3.15

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DFH
SLBT
Founded
2008
N/A
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Homebuilding
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
DFH
SLBT
Price
$13.80
$3.15
Analyst Decision
Hold
Analyst Count
2
0
Target Price
$26.00
N/A
AVG Volume (30 Days)
534.4K
39.9K
Earning Date
05-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.37
N/A
Revenue
$4,322,848,000.00
N/A
Revenue This Year
$0.81
N/A
Revenue Next Year
$7.82
N/A
P/E Ratio
$36.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.20
$2.51
52 Week High
$31.10
$6.25

Technical Indicators

Market Signals
Indicator
DFH
SLBT
Relative Strength Index (RSI) 42.90 53.94
Support Level $12.35 $2.52
Resistance Level $16.47 $3.40
Average True Range (ATR) 0.67 0.19
MACD -0.12 0.10
Stochastic Oscillator 12.15 71.85

Price Performance

Historical Comparison
DFH
SLBT

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

Share on Social Networks: